SECURITIES PURCHASE AGREEMENT


 


 


THIS SECURITIES PURCHASE AGREEMENT (the
“Agreement”) is entered into by and among Zander Therapeutics, Inc., a Nevada corporation (the “Company”)
whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and Hall Family Trust dated 7/21/2003 (“Purchaser”)
a person whose address is 5019 Tierra Del Oro Carlsbad CA.


 


WHEREAS:


 


The Purchaser desires to shares of common
stock in the Company (“Shares”) in accordance with the terms and conditions set forth herein.


 


The Company desires to issue and sell
Shares to the Purchaser in accordance with the terms and conditions set forth herein.


 


THEREFORE, IT IS AGREED AS FOLLOWS


 


 


1. Purchase Price


 


The purchase price per Share (“Purchase Price”),
payable in US Dollars, shall be $2.00 per Share.


 


 


2. Form of Payment


 


The Purchaser shall pay the Purchase
Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately available funds to the Company


WIRE INSTRUCTIONS:


__________________


__________________


 


3. Issuance of Shares


 


5 business days subsequent to receipt
of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares purchased


4. Purchaser’s Representations and Warranties


 


	 	(a)	As of the date hereof, the Purchaser is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the “Act”). 


 


	 	(b)	The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Act


 


	 	(c)	The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Shares which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.


 



    	 	1	 



     


    










 


	 	(d)	Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.


 


	 	(e)	The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.


 


5. Company’s representations and warranties


 


a) Company is a corporation duly organized, validly existing
and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter
into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify,
any person, entity or governmental agency which consent has not been obtained.


(b) The execution, delivery and
performance of this Agreement by Company does not and shall not constitute Company’s breach of any statute or regulation
or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms,
conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a
party, or by which Company is or may be bound.


6. Restricted Securities Acknowledgement


 


Purchaser acknowledges that any
securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act of 1933 shall constitute
“restricted securities” as that term is defined in Rule 144 promulgated under the Act, and shall contain the following
restrictive legend:


“THESE SECURITIES HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT
BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH
LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED
TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”


8. Entire Agreement


This Agreement constitutes a final
written expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete and
exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations
between the parties.


9. Governing Law, Venue, Waiver of Jury Trial


All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party shall
commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding
shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.









    	 	2	 



     


    

 





IN WITNESS WHEREOF, the parties have hereunto executed
this Agreement on the 30th day of January 2018.


	Zander Therapeutics, Inc	 
	/s/ David Koos	 
	David Koos, CEO	 
	Date: 2/22/2018	 


 


	Purchaser	 
	/s/Lance C. Hall 	 
	Loyd Eric Cotson, Trustee	 
	 	 
	 	 
	 	 
	Date: 2/15/2018	 
	Number of Shares Purchased: 50,000
	Total Purchase Price: $100,000